91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In this piece from Clinical Trial Vanguard, Travis Caudill, Vice President, Feasibility, Site Identification & Clinical Informatics explores the improvements in site selection that human-enabled AI is delivering.
-
In this article, Darlene Ellenor Director of Project Operations, Decentralized Clinical Trials Operations highlights how DCTs are now considered a patient centric model for sponsors that want to enhance the patient and site experience and generate more robust data. As DCT evolves, an embedded approach backed by the right processes and tools will maximize the benefits that DCTs bring to clinical research.
-
In this article from Pharmaceutical Executive, Harpreet Gill, VP of Real World Solutions - Project Management, discusses the progress and challenges in advancing data-driven tools and approaches in decentralised clinical trials.
-
In this article in Applied Clinical Trials, Emily Mitchell, Executive Director, eClinical Development and Delivery, outlines how thorough assessment of protocols, whether for DCTs or hybrid clinical trials that incorporate decentralised components, can ensure that studies are designed to minimise patient burden while optimising opportunities to leverage data on a wider scale.
-
In this article on Pharmaceutical Executive’s website, Harpreet Gill discusses how and improve the patient experience.
-
This article by Carrye Nibblelink, Executive Director, Decentralised Clinical Trial Solutions in the Journal of mHealth explores how the throughout their clinical trial journey.
Copyright 2023 The Journal of mHealth (Simidics Ltd)
-
This article in the Journal of mHealth , and is authored by Jo Hulbert, Executive Director, Global Regulatory Clinical Services with contributions from Arwa Shurrab, Senior Director, Global Regulatory Affairs and Priti Prasad, Senior Manager, Global Regulatory Affairs.
Copyright 2023 The Journal of mHealth (Simedics Ltd)
-
Harpreet Gill, Vice President, Decentralised Clinical Trials at 91黑料 reflects on in the last number of years in this article in PharmaTimes.
January/February PharmaTimes
-
As DCT adoption increases, Harpreet Gill, Head of Decentralised Clinical Trial Solutions at 91黑料 contributes to this piece in Clinical Trials Arena which looks at how sponsors and CROs must mind .
Verdict Media Limited 2022
-
Expert Q&A: The impact of the clinical trial liaison function
Expert Q&A: The impact of the clinical trial liaison function
The clinical trial liaison (CTL) function was first introduced in 2014 to help sponsors differentiate themselves from the competition by driving recruitment success in clinical trials.
FirstWord spoke with Elizabeth Pash, Senior Director of Global Site Engagement Operations at 91黑料, to find out exactly what this relatively new role involves, its value in developing and delivering optimal clinical trials and how it is set to evolve in future.
Summary points from the interview:
- In the competitive world of pharmaceutical research, sponsors can differentiate themselves by driving recruitment success in clinical trials.
- The CTL role was introduced in 2014 to bring doctorate-trained clinical research professionals into the clinical trial process to support site identification, activation and recruitment, ensuring optimal productivity of clinical trials.
- While CTLs and clinical research associates (CRAs) are both considered protocol experts and build relationships with sites, CTLs focus on the scientific aspects of a protocol rather than the eligibility criteria and schedule of assessments.
- At 91黑料, CTLs have contributed to a 20% boost in the targeted recruitment rate and helped approximately 70% of sites achieve their baseline recruitment goals. In the past five years, they have also helped sponsors bring nine new compounds to market and receive two new indication approvals for already-approved medications.
- As more clinical trials begin to incorporate more decentralised approaches, the need for roles like CTLs is set to steadily increase across the industry.
- Potential is increasing for CTLs to establish partnerships earlier with sponsors, supporting trial and protocol design, conducting targeted investigator interviews and applying the information in the early stages of clinical development.
[Subscription is required to view the entire interview]
